Format

Send to

Choose Destination
Lancet. 2001 Jul 21;358(9277):207-8.

Linezolid resistance in a clinical isolate of Staphylococcus aureus.

Abstract

The new oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Although instances of linezolid resistance in VRE have been reported, resistance has not been encountered among clinical isolates of S aureus. We have characterised an MRSA isolate resistant to linezolid that was recovered from a patient treated with this agent for dialysis-associated peritonitis.

PMID:
11476839
DOI:
10.1016/S0140-6736(01)05410-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center